Viewing Study NCT06757634

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:24 AM
Ignite Modification Date: 2026-03-06 @ 6:24 AM
Study NCT ID: NCT06757634
Status: RECRUITING
Last Update Posted: 2025-06-18
First Post: 2024-12-24
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Sponsor: Celcuity Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer, Advanced or Metastatic View
None Gedatolisib View
None HR Positive View
None ER Positive View
None HER2 Negative View
None PIK3CA MT View
None PI3K View